Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionSelective ataxia telangiectasia and Rad3 related (ATR; FRP1) inhibitor
Molecular Target Ataxia telangiectasia and Rad3 related (ATR) (FRP1)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today